PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32789786-5 2020 In the present literature review, we put together this studies and provide integrated evidence that exhibits berberine has the potential atheroprotective effect through reducing increased levels of plasma cholesterol, particularly low-density lipoprotein (LDL) cholesterol (LDL-C) via LDL receptor (LDLR)-dependent and LDL receptor-independent mechanisms, inhibiting migration and inflammatory activity of macrophages, improving the functionality of endothelial cells via anti-oxidant activities, and suppressing proliferation of vascular smooth muscle cells. Berberine 109-118 low density lipoprotein receptor Homo sapiens 285-297 35217376-2 2022 Berberine, californidine and govaniadine induced LDLR with an effect similar to 2.5 microM simvastatin. Berberine 0-9 low density lipoprotein receptor Homo sapiens 49-53 32001311-3 2020 At a cellular level, the inhibitory effect of BBR on mitochondrial enzymes is probably responsible for many of its biological activities, including the activation of low-density lipoprotein receptor (LDLR), AMP-activated protein kinase (AMPK) and insulin receptor (InsR); these biological activities contribute to ameliorate peripheral blood metabolic profiles, e.g. by reducing plasma lipids and glucose levels, thus improving signs and symptoms of metabolic disorders. Berberine 46-49 low density lipoprotein receptor Homo sapiens 166-198 32001311-3 2020 At a cellular level, the inhibitory effect of BBR on mitochondrial enzymes is probably responsible for many of its biological activities, including the activation of low-density lipoprotein receptor (LDLR), AMP-activated protein kinase (AMPK) and insulin receptor (InsR); these biological activities contribute to ameliorate peripheral blood metabolic profiles, e.g. by reducing plasma lipids and glucose levels, thus improving signs and symptoms of metabolic disorders. Berberine 46-49 low density lipoprotein receptor Homo sapiens 200-204 34790723-11 2021 Finally, in vitro study showed that BBR promoted intracellular cholesterol efflux, up-regulated LDLR and down-regulated PCSK9 expression via the ERK1/2 pathway in cultured HepG2 cells. Berberine 36-39 low density lipoprotein receptor Homo sapiens 96-100 32789786-5 2020 In the present literature review, we put together this studies and provide integrated evidence that exhibits berberine has the potential atheroprotective effect through reducing increased levels of plasma cholesterol, particularly low-density lipoprotein (LDL) cholesterol (LDL-C) via LDL receptor (LDLR)-dependent and LDL receptor-independent mechanisms, inhibiting migration and inflammatory activity of macrophages, improving the functionality of endothelial cells via anti-oxidant activities, and suppressing proliferation of vascular smooth muscle cells. Berberine 109-118 low density lipoprotein receptor Homo sapiens 299-303 32789786-5 2020 In the present literature review, we put together this studies and provide integrated evidence that exhibits berberine has the potential atheroprotective effect through reducing increased levels of plasma cholesterol, particularly low-density lipoprotein (LDL) cholesterol (LDL-C) via LDL receptor (LDLR)-dependent and LDL receptor-independent mechanisms, inhibiting migration and inflammatory activity of macrophages, improving the functionality of endothelial cells via anti-oxidant activities, and suppressing proliferation of vascular smooth muscle cells. Berberine 109-118 low density lipoprotein receptor Homo sapiens 319-331 27015087-0 2016 Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine. Berberine 133-142 low density lipoprotein receptor Homo sapiens 20-24 30563192-7 2018 In addition, the combination of berberine with resveratrol significantly increases the low-density-lipoprotein receptor expression in HepG2 cells to a level about one-fold higher in comparison to individual compound. Berberine 32-41 low density lipoprotein receptor Homo sapiens 87-119 30563192-8 2018 These results implied that the enhanced effect of the combination of berberine with resveratrol on lipid-lowering may be associated with upregulation of low-density-lipoprotein receptor, and could be an effective therapy for hyperlipidemia in some obese-associated disease, such as type II diabetes and metabolic syndrome. Berberine 69-78 low density lipoprotein receptor Homo sapiens 153-185 30335889-1 2018 Berberine (BBR), the major isoquinoline alkaloid in Chinese herb Rhizoma coptidis, has significant lipid-lowering effect by upregulating hepatic low-density lipoprotein receptor (LDLR) expression. Berberine 0-9 low density lipoprotein receptor Homo sapiens 145-177 30335889-1 2018 Berberine (BBR), the major isoquinoline alkaloid in Chinese herb Rhizoma coptidis, has significant lipid-lowering effect by upregulating hepatic low-density lipoprotein receptor (LDLR) expression. Berberine 0-9 low density lipoprotein receptor Homo sapiens 179-183 30335889-1 2018 Berberine (BBR), the major isoquinoline alkaloid in Chinese herb Rhizoma coptidis, has significant lipid-lowering effect by upregulating hepatic low-density lipoprotein receptor (LDLR) expression. Berberine 11-14 low density lipoprotein receptor Homo sapiens 145-177 30335889-1 2018 Berberine (BBR), the major isoquinoline alkaloid in Chinese herb Rhizoma coptidis, has significant lipid-lowering effect by upregulating hepatic low-density lipoprotein receptor (LDLR) expression. Berberine 11-14 low density lipoprotein receptor Homo sapiens 179-183 24317011-4 2014 The overall potential of the antioxidant system was significantly enhanced by the PME, berberine and glycyrrhizin supplements as the plasma and hepatic TBARS levels were lowered while the hepatic superoxide dismutase activity and glutathione levels, HMG-CoA reductase, LDL receptor, PPAR, SREBP-2 and CYP7A1 mRNA expressions were increased by the treatments of PME and berberine in comparison with the high cholesterol fed hamsters (P < 0.05). Berberine 87-96 low density lipoprotein receptor Homo sapiens 269-281 26310319-2 2015 Mechanistic studies have shown that BBR activates the extracellular-signal regulated kinase pathway by stabilizing low-density-lipoprotein receptor mRNA. Berberine 36-39 low density lipoprotein receptor Homo sapiens 115-147 24321576-0 2014 Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells. Berberine 0-9 low density lipoprotein receptor Homo sapiens 35-67 24321576-5 2014 Here, RT-PCR, Western blotting and Oil Red O staining were used to investigate the effects of four BBR metabolites on LDLR expression and lipid accumulation in human hepatoma Hep G2 cells. Berberine 99-102 low density lipoprotein receptor Homo sapiens 118-122 24321576-7 2014 Four metabolites of BBR, jatrorrhizine, columbamine, berberrubine and demethyleneberberine, were found to be able to up-regulate LDLR mRNA and protein expression. Berberine 20-23 low density lipoprotein receptor Homo sapiens 129-133 23058107-0 2012 Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation. Berberine 49-58 low density lipoprotein receptor Homo sapiens 72-76 23139291-6 2013 As apoE is a potent ligand for the LDL receptor, we next evaluated the effects of TOR in combination with the LDL-lowering drug berberine, which upregulates LDL receptor expression in dyslipidemic hamsters. Berberine 128-137 low density lipoprotein receptor Homo sapiens 157-169 23058107-2 2012 A series of new derivatives of berberine (BBR) or pseudoberberine (1) was synthesized and evaluated for their activity on AMP-activated protein kinase (AMPK) activation and up-regulatory low-density-lipoprotein receptor (LDLR) gene expression, respectively. Berberine 31-40 low density lipoprotein receptor Homo sapiens 187-219 23058107-2 2012 A series of new derivatives of berberine (BBR) or pseudoberberine (1) was synthesized and evaluated for their activity on AMP-activated protein kinase (AMPK) activation and up-regulatory low-density-lipoprotein receptor (LDLR) gene expression, respectively. Berberine 31-40 low density lipoprotein receptor Homo sapiens 221-225 23058107-2 2012 A series of new derivatives of berberine (BBR) or pseudoberberine (1) was synthesized and evaluated for their activity on AMP-activated protein kinase (AMPK) activation and up-regulatory low-density-lipoprotein receptor (LDLR) gene expression, respectively. Berberine 42-45 low density lipoprotein receptor Homo sapiens 187-219 17767919-0 2007 Berberine-induced LDLR up-regulation involves JNK pathway. Berberine 0-9 low density lipoprotein receptor Homo sapiens 18-22 18640378-1 2008 We have identified berberine (BBR) as a novel cholesterol-lowering drug acting through stabilization of the low-density lipoprotein receptor (LDLR) messenger RNA. Berberine 19-28 low density lipoprotein receptor Homo sapiens 108-140 18640378-1 2008 We have identified berberine (BBR) as a novel cholesterol-lowering drug acting through stabilization of the low-density lipoprotein receptor (LDLR) messenger RNA. Berberine 19-28 low density lipoprotein receptor Homo sapiens 142-146 18640378-1 2008 We have identified berberine (BBR) as a novel cholesterol-lowering drug acting through stabilization of the low-density lipoprotein receptor (LDLR) messenger RNA. Berberine 30-33 low density lipoprotein receptor Homo sapiens 108-140 18640378-1 2008 We have identified berberine (BBR) as a novel cholesterol-lowering drug acting through stabilization of the low-density lipoprotein receptor (LDLR) messenger RNA. Berberine 30-33 low density lipoprotein receptor Homo sapiens 142-146 18640378-3 2008 Our results showed that combination of BBR with simvastatin (SIMVA) increased the LDLR gene expression to a level significantly higher than that in monotherapies. Berberine 39-42 low density lipoprotein receptor Homo sapiens 82-86 17767919-2 2007 However, considering the complexity of interconnected signal pathways in biological processes, it is highly possible that there exist signal pathway(s) other than ERK pathway which contribute to the berberine-induced up-regulation of LDLR. Berberine 199-208 low density lipoprotein receptor Homo sapiens 234-238 17767919-3 2007 In the present study, we examined possible involvement of other signal pathways in berberine-induced hepatic LDLR up-regulation. Berberine 83-92 low density lipoprotein receptor Homo sapiens 109-113 17767919-4 2007 As evidenced by RT-PCR, berberine-induced LDLR mRNA expression was inhibited by JNK inhibitor SP600125 pretreatment. Berberine 24-33 low density lipoprotein receptor Homo sapiens 42-46 17767919-5 2007 Furthermore, we demonstrate that putative c-jun binding site of LDLR promoter is important in berberine-induced LDLR transcription using luciferase assay. Berberine 94-103 low density lipoprotein receptor Homo sapiens 64-68 17767919-5 2007 Furthermore, we demonstrate that putative c-jun binding site of LDLR promoter is important in berberine-induced LDLR transcription using luciferase assay. Berberine 94-103 low density lipoprotein receptor Homo sapiens 112-116 17767919-6 2007 The result of EMSA also shows that berberine induces c-jun binding to LDLR promoter and this is decreased by SP600125 pretreatment. Berberine 35-44 low density lipoprotein receptor Homo sapiens 70-74 17767919-7 2007 The present study demonstrates that berberine increases transcriptional activity of LDLR promoter and this involves JNK pathway. Berberine 36-45 low density lipoprotein receptor Homo sapiens 84-88 19800225-0 2009 Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor. Berberine 39-48 low density lipoprotein receptor Homo sapiens 91-123 19800225-1 2009 Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR). Berberine 0-9 low density lipoprotein receptor Homo sapiens 74-106 19800225-1 2009 Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR). Berberine 0-9 low density lipoprotein receptor Homo sapiens 108-112 19800225-1 2009 Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR). Berberine 11-14 low density lipoprotein receptor Homo sapiens 74-106 19800225-1 2009 Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR). Berberine 11-14 low density lipoprotein receptor Homo sapiens 108-112 19687008-4 2009 Interestingly, the plant-derived hypocholesterolemic compound berberine (BBR) up-regulates LDLR expression while down-regulating PCSK9. Berberine 62-71 low density lipoprotein receptor Homo sapiens 91-95 19687008-4 2009 Interestingly, the plant-derived hypocholesterolemic compound berberine (BBR) up-regulates LDLR expression while down-regulating PCSK9. Berberine 73-76 low density lipoprotein receptor Homo sapiens 91-95 18355829-6 2008 We also show that a combination of berberine and mevastatin increases LDLR mRNA and protein levels, while suppressing the increase in PCSK9 mRNA levels caused by mevastatin alone. Berberine 35-44 low density lipoprotein receptor Homo sapiens 70-74 18644725-0 2008 Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators. Berberine 50-59 low density lipoprotein receptor Homo sapiens 90-122 18644725-1 2008 Berberine (BBR, 1) is a novel cholesterol-lowering agent that up-regulates low-density-lipoprotein receptor (LDLR) expression through a mechanism different from that of statins. Berberine 0-9 low density lipoprotein receptor Homo sapiens 75-107 18644725-1 2008 Berberine (BBR, 1) is a novel cholesterol-lowering agent that up-regulates low-density-lipoprotein receptor (LDLR) expression through a mechanism different from that of statins. Berberine 0-9 low density lipoprotein receptor Homo sapiens 109-113 18644725-1 2008 Berberine (BBR, 1) is a novel cholesterol-lowering agent that up-regulates low-density-lipoprotein receptor (LDLR) expression through a mechanism different from that of statins. Berberine 11-14 low density lipoprotein receptor Homo sapiens 75-107 18644725-1 2008 Berberine (BBR, 1) is a novel cholesterol-lowering agent that up-regulates low-density-lipoprotein receptor (LDLR) expression through a mechanism different from that of statins. Berberine 11-14 low density lipoprotein receptor Homo sapiens 109-113 17767919-1 2007 Berberine, an herbal alkaloid, has been reported to have a lipid lowering effect by stabilizing hepatic LDLR mRNA in an ERK-dependent manner rather than promoting transcriptional activity. Berberine 0-9 low density lipoprotein receptor Homo sapiens 104-108 16890192-1 2006 Berberine (BBR), a compound purified from Cortidis rhizoma, reduces serum cholesterol, triglycerides, and LDL-cholesterol of hypercholesterolemic patients and high fat diet fed animals, and increases hepatic LDLR mRNA and protein levels through a post-transcriptional mechanism. Berberine 0-9 low density lipoprotein receptor Homo sapiens 208-212 16890192-1 2006 Berberine (BBR), a compound purified from Cortidis rhizoma, reduces serum cholesterol, triglycerides, and LDL-cholesterol of hypercholesterolemic patients and high fat diet fed animals, and increases hepatic LDLR mRNA and protein levels through a post-transcriptional mechanism. Berberine 11-14 low density lipoprotein receptor Homo sapiens 208-212 16508037-1 2006 The alkaloid drug berberine (BBR) was recently described to decrease plasma cholesterol and triglycerides (TGs) in hypercholesterolemic patients by increasing expression of the hepatic low density lipoprotein receptor (LDLR). Berberine 18-27 low density lipoprotein receptor Homo sapiens 185-217 16508037-1 2006 The alkaloid drug berberine (BBR) was recently described to decrease plasma cholesterol and triglycerides (TGs) in hypercholesterolemic patients by increasing expression of the hepatic low density lipoprotein receptor (LDLR). Berberine 18-27 low density lipoprotein receptor Homo sapiens 219-223 16508037-1 2006 The alkaloid drug berberine (BBR) was recently described to decrease plasma cholesterol and triglycerides (TGs) in hypercholesterolemic patients by increasing expression of the hepatic low density lipoprotein receptor (LDLR). Berberine 29-32 low density lipoprotein receptor Homo sapiens 185-217 16508037-1 2006 The alkaloid drug berberine (BBR) was recently described to decrease plasma cholesterol and triglycerides (TGs) in hypercholesterolemic patients by increasing expression of the hepatic low density lipoprotein receptor (LDLR). Berberine 29-32 low density lipoprotein receptor Homo sapiens 219-223 15926873-2 2005 Berberine upregulates the LDL receptor (LDLR) by a mechanism distinct from that of the statins, which involves stabilising the LDLR mRNA. Berberine 0-9 low density lipoprotein receptor Homo sapiens 26-38 15926873-2 2005 Berberine upregulates the LDL receptor (LDLR) by a mechanism distinct from that of the statins, which involves stabilising the LDLR mRNA. Berberine 0-9 low density lipoprotein receptor Homo sapiens 40-44 15926873-2 2005 Berberine upregulates the LDL receptor (LDLR) by a mechanism distinct from that of the statins, which involves stabilising the LDLR mRNA. Berberine 0-9 low density lipoprotein receptor Homo sapiens 127-131 15926873-7 2005 As berberine and statins both upregulate LDLR, their lipid-lowering profiles are similar. Berberine 3-12 low density lipoprotein receptor Homo sapiens 41-45 15531889-4 2004 Using human hepatoma cells, we show that BBR upregulates LDLR expression independent of sterol regulatory element binding proteins, but dependent on ERK activation. Berberine 41-44 low density lipoprotein receptor Homo sapiens 57-61